Compare PNNT & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | NERV |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 210.1M |
| IPO Year | 2007 | 2014 |
| Metric | PNNT | NERV |
|---|---|---|
| Price | $3.71 | $4.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.75 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 573.9K | 151.9K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 20.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $1.76 |
| 52 Week High | $7.53 | $12.46 |
| Indicator | PNNT | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 51.96 |
| Support Level | $3.61 | $3.80 |
| Resistance Level | $3.92 | $4.70 |
| Average True Range (ATR) | 0.11 | 0.34 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 86.87 | 71.08 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.